Pseudomyxoma peritonei (PMP): carcinomatosis of appendiceal origin

Highly precise diagnosis and specialist management of PMP

Receiving a diagnosis of pseudomyxoma peritonei (PMP) or appendix cancer can bring considerable uncertainty, fear and questions. This is a rare condition, and assessing it requires highly specialised expertise. At the Peritoneal Cancer Institute, we specialise in second opinions and highly complex cases. Do not assume that your current diagnosis is definitive; we are here to help review your case with the utmost precision.

Understanding mucinous tumours of the appendix

The clinical challenge of a rare disease: highly specialised care

Pseudomyxoma peritonei (PMP), which usually develops from an appendiceal mucinous tumour, is a unique clinical condition. When a lesion in the appendix, such as a low-grade appendiceal mucinous neoplasm (LAMN) or a high-grade appendiceal mucinous neoplasm (HAMN), ruptures, it releases tumour material into the abdominal cavity.

This tumour material consists mainly of mucin, a jelly-like substance that gradually accumulates and may contain mucus alone or mucus with a cellular component. The characteristics and aggressiveness of this cellular component determine the patient’s prognosis.

Unlike other types of peritoneal carcinomatosis, pseudomyxoma peritonei usually grows slowly and progressively, and very rarely spreads to other organs through the bloodstream or lymphatic system. Its main characteristic is the expanding accumulation of this “jelly” in the abdomen, which gradually compresses organs such as the small intestine, colon, stomach and liver, as well as other structures, causing severe pain and abdominal distension.

The tumour is usually asymptomatic. Understanding what PMP means in medical terms is your first step towards managing it: it does not behave like a conventional cancer, but rather as a syndrome of progressive compression that requires expert care.

Why your initial prognosis for pseudomyxoma peritonei does not define all your options

Expert oncological reassessment: an active, personalised treatment strategy

Patients with disseminated appendiceal mucinous neoplasms are very often told at a general hospital that their disease is inoperable. Because the condition is rare, most centres offer only palliative care. Others offer inappropriate treatments that can compromise outcomes and the prognosis of the disease. We take a radically different approach.

Exclusive specialisation in the peritoneum

We understand precisely how appendiceal mucinous tumours behave. The extent of tumour spread within the abdominal cavity does not deter us; we are specifically trained to address and manage it.

Beyond palliative treatment

While other protocols focus solely on draining fluid or mucin and temporarily relieving your symptoms, our medical goal is to stop the progression of the disease at its source.

Reassessing inoperability

Many patients initially considered “inoperable” are successfully treated at our Peritoneal Cancer Institute. We have the team and technical expertise required to manage this unusual tumour.

Specialist surgical treatment for appendiceal mucinous tumours

We treat the tumour using the most advanced surgical technique to improve your prognosis and protect your quality of life

Treating appendix cancer requires the utmost precision and a carefully controlled, extensive surgical approach. Our approach combines the complete and meticulous removal of all visible tumour using specialised, standardised surgical techniques with drug therapy delivered directly into the abdominal cavity.

Complete cytoreductive surgery

Our surgeons meticulously remove all visible tumour deposits, affected tissues and/or organs, and all the mucin accumulated in your abdomen.

We administer heated liquid chemotherapy directly into the abdominal cavity. This solution penetrates the tissues, eliminating any microscopic tumour deposits that may remain after such extensive surgery.

We use drugs such as mitomycin C or oxaliplatin at a controlled temperature of 42°C, which have been shown to be highly effective in destroying mucinous tumours.

This is a complex and extensive procedure designed to remove all visible disease. However, every resection is meticulously planned to preserve your functional abilities and ensure the best possible long-term quality of life.

Assessing whether surgery is possible for your appendiceal tumour

Assessment and eligibility: your available options

To determine whether you are eligible for our treatments, we need to carefully assess your medical history, imaging scans, tumour biology and how the tumour has progressed. A key factor in this process is the Peritoneal Cancer Index (PCI).

Unlike other forms of peritoneal metastasis, pseudomyxoma peritonei can have a high Peritoneal Cancer Index, meaning a large amount of visible mucin, without automatically ruling out surgery. What matters most is assessing how this mucin is distributed and whether it can be removed without damaging vital structures.

Our multidisciplinary medical team analyses these factors, together with your baseline health, to design the safest and most effective strategy, even when other specialists have ruled out surgery.


Prognosis and outcomes: a realistic, scientific perspective

Scientific evidence and complete clinical transparency

Searching for information about survival in pseudomyxoma peritonei can feel overwhelming, but current scientific evidence provides grounds for realistic hope. It is essential to understand that prognosis varies from patient to patient; it depends directly on whether the cells are low-grade or high-grade, how advanced the disease is within your abdomen, and the surgical expertise of the treating team.

In favourable cases of low-grade appendiceal mucinous neoplasm (LAMN) with acellular or sparsely cellular mucin, complete surgical clearance is performed, meaning total cytoreduction combined with HIPEC. International statistics show 10-year survival rates exceeding 80%. In these situations, we work with a clear intention to achieve a cure and very long-term disease control.

In advanced cases with a high intra-abdominal tumour burden (LAMN or HAMN) and highly cellular mucin, the approach is the same. Our primary goal is to achieve complete cytoreduction to eradicate all visible tumour and treat any microscopic residual disease with HIPEC. In these more complex situations, a specialist approach achieves a somewhat lower cure rate than in the previous scenario, but substantially improves survival and quality of life compared with palliative care alone.

Our commitment is to assess the true extent of your disease and propose specialist treatment with honest expectations, based on scientific evidence, while offering you all available treatment options.

Real patient stories: the impact of highly specialised care

Frequently asked questions about pseudomyxoma peritonei

What does PMP stand for in medicine?

In medicine, PMP stands for pseudomyxoma peritonei, a complex clinical syndrome characterised by the accumulation of mucin, a jelly-like substance, in the abdominal cavity following the rupture of a mucinous tumour. This tumour originates in the appendix in 95% of cases. In the remaining 5%, it may originate in the ovary, urachus, gallbladder, pancreas or other intra-abdominal organs.

A low-grade appendiceal mucinous neoplasm (LAMN) is not a cancer with highly aggressive cellular behaviour. However, if it ruptures, it gives rise to PMP, progressively invading the peritoneum and the surfaces of the abdominal organs.

LAMN is a low-grade appendiceal mucinous neoplasm, whereas HAMN is a high-grade appendiceal mucinous neoplasm. Because of its characteristics, HAMN is slightly more aggressive than LAMN, although the surgical treatment is the same. A “radical” appendicectomy should be performed in both cases, and never a right colectomy, as sometimes occurs at centres that do not specialise in this condition. PMP only develops when a LAMN or HAMN ruptures and releases mucin into the abdominal cavity.

Following radical surgery, and provided that the tumour has not ruptured and released mucin into the abdominal cavity, LAMN and HAMN have the same prognosis, with complete cure. If the primary tumour ruptures and PMP is subsequently diagnosed, the prognosis and treatment are different.

The mucin surrounding peritoneal mucinous lesions acts as an impenetrable barrier. In addition, the mucin often contains few tumour cells, which are the main target of chemotherapy drugs. It is also important to remember that a natural barrier, known as the peritoneal–plasma barrier, prevents intravenous chemotherapy from reaching the peritoneum at its full concentration.

For all these reasons, systemic chemotherapy is not usually indicated for this type of tumour. It may be recommended only in exceptional cases, generally when there is a high tumour burden, high cellularity and incomplete surgical removal of the disease.


This is the gold-standard treatment for this condition. First, all visible tumour and mucin are removed using specialised surgical techniques, namely the peritonectomy procedures described by Dr Paul Sugarbaker. Immediately afterwards, in the same operating theatre, the abdomen is bathed for 60–90 minutes in a sterile solution containing chemotherapy drugs, heated to 42°C, to eliminate microscopic tumour deposits that cannot be seen. This is a complex, extensive and lengthy operation, lasting between 8 and 14 hours, but it is safe when performed at specialist centres.

Not necessarily. We assess your “biological age” and overall physical condition. Patients who are physically fit frequently undergo successful surgery regardless of their chronological age.

In pseudomyxoma peritonei, we do not use the term “metastasis” in its usual sense. With radical surgical treatment (CRS + HIPEC) at a highly specialised centre, a high proportion of patients achieve long-term remission and even a definitive cure.

Because this is an extensive procedure, you will need to spend 2–3 weeks in hospital, followed by 2–4 months of gradual recovery at home before returning to your usual physical activities. These times depend on several factors, including the initial tumour burden, the extent of surgery and the surgical team’s experience.

It is a rare disease, with an estimated incidence of 1–2 cases per million people each year. It is understandable that doctors outside the field of peritoneal surgical oncology may not be familiar with it.

An assessment by a team specialising in peritoneal neoplasms is always necessary. The vast majority of hospitals lack the specialists and infrastructure needed to treat advanced cases of pseudomyxoma peritonei. That is why it is vital to seek a second assessment from an expert medical team such as the Peritoneal Cancer Institute.

The next step: an expert second opinion

Your situation requires a thorough, expert medical assessment by professionals who truly understand the nature of pseudomyxoma peritonei. Do not let a diagnosis limit your future options.

Our medical and surgical team simply needs to review your medical history to offer you the latest advances in the treatment of this little-known condition.

Thank you very much for filling out the contact form!

We will get back to you as soon as possible.

Thank you very much for filling out the contact form!

We will get back to you as soon as possible.